bioRxiv Science⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.1101/2024.11.28.625954

Reevaluating the Association Between Epstein-Barr Virus (EBV) and Breast Cancer in the United States

Hu, C. C.·Kamtam, D. N.·Cardona, J. J.
View original source ↗Export metadata ↓

Abstract

The World Health Organization estimates 9.9% of cancers are attributable to viruses. Notably, human papillomavirus causes roughly 90% of cervical cancers, while Epstein-Barr virus (EBV) is linked to nearly 10% of gastric carcinomas. Regarding breast cancer, the association with EBV is inconclusive. While studies in some nations report an association, those in the United States largely do not. We reviewed studies from 2003 to 2023 and identified seven that analyzed EBV association with breast cancer in American patients. We observed a potential risk of not investigating novel EBV variants. Detection protocols utilized only lymphoma-derived strains, despite the current knowledge suggesting that genotype variation can influence pathogenic potential and cell tropism. Certain EBV strains, for instance, may preferentially infect epithelial cells and increase the risk of nasopharyngeal carcinoma (NPC) by up to 11 times. Stated simply, the optimal EBV detection protocol for breast cancer cells may differ from lymphoma cells. Reliance on lymphoma-derived strains assumes a level of sequence conservation among EBV genomes. Mounting evidence demonstrates greater variation than previously believed, especially in key coding and non-coding regions. Our analysis reveals that 5/7 (71%) studies used at least one assay sequence that did not exactly match more than 50% of EBV genomes in NCBI GenBank. Moreover, 98% of these GenBank entries became available after assay sequences were selected. Overall, it is possible the current understanding may be incomplete. Should breast cancer mirror gastric carcinoma and exhibit EBV influence in certain subtypes, these insights could enable targeted therapies and screening programs. ObjectivesThis study examines potential limitations of prior investigations into the association between Epstein-Barr Virus (EBV) and breast cancer in the United States. Specifically, our aims are to: O_LIAssess the cellular origin and pathogenicity of EBV strains employed in detection protocols. This objective stems from the background sections discussion on EBV genotype variations and their potential influence on tissue tropism and pathogenic mechanisms. C_LIO_LIEvaluate the sequence similarity between assay sequences and available EBV genomic data. This objective addresses the concern raised in the background section regarding the potential for newfound sequence variation among EBV strains and the implications for accurate detection. C_LIO_LIDetermine the extent to which detection protocols incorporate the latest EBV genomic data. C_LI

Explore related subjects

cancer biologyPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Hu, C. C., Kamtam, D. N., Cardona, J. J.. 2024-12-02. Reevaluating the Association Between Epstein-Barr Virus (EBV) and Breast Cancer in the United States. https://doi.org/10.1101/2024.11.28.625954

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

m6A-Driven Intratumoral Cholesterol Biosynthesis Fuels Castration-Resistant Prostate Cancer Progression

Both nuclear pore complexes (NPCs) and RNA N6-methyladenosine (m6A) machinery are indispensable for proper cellular function. Although their collaborative roles in the nuclear export of messenger RNAs (mRNAs) have been reported, it remains ambiguous whether and how this collaboration may contribute to cancer progression. Here we identify a functional cooperation between NPCs and m6A signaling that promotes the development of castration-resistant prostate cancer (CRPC). We showed that nuclear export of m6A-modified mRNAs, mediated by the interaction between RNA methyltransferase METTL3 and the nucleoporin NUP93, is functionally coupled to cholesterol biosynthesis. Given that cholesterol-fueled intratumoral androgen production is one of the mechanisms driving CRPC, we demonstrated that overexpression of the wild-type METTL3 or NUP93, but neither the enzymatically dead METTL3 nor the mutant NUP93 that loses METTL3-interacting capability, elevates intracellular levels of androgens, activates AR signaling under castrate condition, and promotes androgen-independent growth of prostate cancer cells both in vitro and in vivo. Importantly, pharmacological inhibition of METTL3 or targeted demethylation on mRNAs encoding key cholesterol biosynthesis enzymes effectively suppressed CRPC malignancy. Together, these findings uncover a therapeutically targetable m6A-METTL3-NUP93 axis that links nuclear mRNA export and metabolic reprogramming to fuel CRPC progression, providing a conceptually new strategy for the treatment of this lethal disease.

cancer biology↗
bioRxiv2026

ST6Gal2 promotes α2,6-sialylation and aggressive phenotypes in neuroblastoma cells

Neuroblastoma is the most common extracranial solid tumor of childhood. Its clinical behavior ranges from spontaneous regression to lethal, treatment-refractory disease. Aberrant 2,6-sialylation contributes to aggressive phenotypes in many cancers, but the role of ST6Gal2, a neural-enriched 2,6-sialyltransferase, in neuroblastoma is largely unexplored. Here, we examine the clinical and functional significance of ST6Gal2 in neuroblastoma. In two independent public cohorts (SEQC, n=498; Kocak, n=649), high ST6GAL2 expression was associated with significantly worse overall and event-free survival. In the SEQC cohort, ST6GAL2 expression was higher in high-risk and MYCN-amplified tumors, varied across International Neuroblastoma Staging System stages, and correlated positively with a mesenchymal transcriptional signature (Spearman {rho}=0.181). The mesenchymal correlation was reproduced in the Kocak cohort ({rho}=0.204). Stable shRNA-mediated knockdown of ST6GAL2 in SK-N-AS and SK-N-BE(2) cells reduced proliferation and viability, impaired wound closure, and decreased migration and invasion. In preliminary experiments in SK-N-AS cells, ST6GAL2 knockdown reduced binding of Sambucus nigra agglutinin, consistent with a role for ST6Gal2 in 2,6-sialylation. Together, these findings link ST6Gal2 expression to aggressive clinical and transcriptional features and pro-tumorigenic phenotypes in neuroblastoma and nominate ST6Gal2-mediated sialylation as a candidate pathway for mechanistic study.

cancer biology↗
bioRxiv2026

Unsupervised transcriptomic analysis of paired pre- and post-treatment specimens reveals divergent chemoimmunomodulatory induction trajectories in breast cancer

The immunomodulatory effects of chemotherapy (chemoimmunomodulation; CIM) are clinically consequential and heterogeneous, yet no systematic framework exists for classifying the immunomodulatory trajectory a tumor follows in response to treatment (CIM trajectory). Here, we present the CIM Induction Classifier (CIMIC), an unsupervised clustering pipeline leveraging delta gene expression across 3,189 CIM-related genes to classify specimens chemoimmunomodulatory trajectory. Applied to two pre- and post-chemotherapy breast cancer (BC) datasets (NKI/SMC, N = 36; NEO, N = 19) and nine epirubicin-perturbed triple-negative BC (TNBC) cell lines, CIMIC identified two divergent CIM trajectories: a functional CIM (Fun-CIM) trajectory, broadly conserved across tumors and cell lines and characterized by induction of inflammatory cell death, antigen presentation, viral mimicry, and adaptive immune activation programs, and a dysfunctional CIM (Dys-CIM) trajectory, characterized by induction of proteostatic and metabolic stress-adaptation programs, reduced immune cell abundances and cytotoxic activity, and enrichment of aggressive BC subtypes. Using survival and longitudinal transcriptomic data in NKI/SMC (N = 20), treatment-induced increases in Fun-CIM-associated genes and ssGSEA scores were associated with reduced recurrence, whereas Dys-CIM-associated genes and scores were associated with increased recurrence. In multivariable analyses within independent chemotherapy-treated BC cohorts (METABRIC, N = 412; SCAN-B, N = 2,462), higher baseline Fun-CIM ssGSEA scores were associated with better outcomes, whereas higher baseline Dys-CIM ssGSEA scores were associated with worse outcomes. These findings establish CIM as a dynamic, trajectory-level process and position CIMIC as a framework for defining CIM trajectories and supporting future efforts to identify predictors, mechanisms, and therapeutic strategies that maximize beneficial CIM.

cancer biology↗